Company Announcements

Diaceutics PLC - Board Changes

Cheryl MacDiarmid joining as a Non-Executive Director

Graham Paterson becoming Senior Independent Director

Jordan Clark joining as an Executive Director

Mike Wort resigning as a Non-Executive Director

Belfast and London, 1 October 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, today announces the following changes to its board of directors ("Board").

Jordan Clark (Chief Data Officer of Diaceutics) will join the Board as an Executive Director effective 1 October 2024. Cheryl MacDiarmid will join the Board as a Non-Executive Director subject to the completion of usual Nominated Adviser due diligence checks and a further announcement will be made in due course. Having been on the Board since March 2019, Mike Wort is stepping down as a Non-Executive Director effective 1 October 2024. Graham Paterson who is currently a Non-Executive Director of Diaceutics will assume the role of Senior Independent Director effective 1 October, 2024.

In addition, further to the 23 July 2024 announcement, Diaceutics confirms that Deborah Davis has stepped down from the Board with effect from 1 October 2024 and Peter Keeling has succeeded Deborah as Non-Executive Chair.

Cheryl MacDiarmid has over 30 years' experience in the global pharmaceutical sector, notably with GSK, ViiV Healthcare and currently as a Non-Executive Director of AIM-listed Allergy Therapeutics. Cheryl is an internationally recognised opinion leader in the development & commercialisation of medicines. Trained as a pharmacist, she has held numerous senior leadership positions in the UK, EU, US and Canada, with responsibilities including global commercial strategy, P&L, sales, marketing, operations and Board membership. Cheryl is passionate about bringing new therapies to the right patients who can benefit.   

Jordan Clark is Chief Data Officer at Diaceutics. Jordan spearheads Diaceutics' comprehensive data strategy, spanning acquisition engineering and data science, to deliver cutting-edge analytics to our clients and laboratories. With over a decade of experience at Diaceutics, he has cultivated a profound understanding of the critical role real-world data plays in optimising precision medicine. Jordan's academic and professional credentials in biomedical and clinical sciences, coupled with his state licensure as a haematology scientist, underscore his expertise. Additionally, Jordan is renowned for proficiency testing, bioinformatics and biomarker testing, honed through his involvement with UK NEQAS. 

Peter Keeling, Non-Executive Chair of Diaceutics commented: "I would like to thank Mike for his valuable counsel around the IPO process and his useful insights and support to expanding our UK data assets. We will miss him and wish him well in his future endeavours.

I am delighted to warmly welcome Cheryl and Jordan to the Board of Diaceutics. They both bring a significant depth of talent and vast experience as leaders in their field to Diaceutics and I know their insights will play a significant part in helping drive our continued performance and growth in the years ahead."

The following information is disclosed in accordance with Schedule 2(g) of the AIM Rules for Companies:

Additional information with regard to Jordan Clark:

Jordan Russell Clark, age 40, is currently or has been a director of the following companies within the past five years:

Additional information with regard to Cheryl MacDiarmid:

The Company will make a further RNS announcement in due course detailing the disclosures required under Schedule 2(g) of the AIM Rules for Companies.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.